Articles from Indapta Therapeutics, Inc.

Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated immunotherapies for the treatment of cancer and autoimmune diseases, today announced that complete Phase 1 data for IDP-023, the Company’s allogeneic g-NK cell therapy, in combination with isatuximab in patients with relapsed/refractory multiple myeloma (RRMM) will be featured in an oral presentation at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting, taking place November 4–8, 2026, in Phoenix, Arizona.

Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated immunotherapies for the treatment of cancer and autoimmune diseases, today announced the presentation of data highlighting the clinical activity of IDP-023, the Company’s allogeneic g-NK cell therapy, in patients with relapsed/refractory multiple myeloma. IDP-023 treatment was given as a standalone therapy and in combination with isatuximab, an anti-CD38 monoclonal antibody approved for the treatment of multiple myeloma.

Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated cell therapies for the treatment of cancer and autoimmune diseases, today announced a collaboration with Sanofi to explore the combination of its allogeneic g-NK cell therapy, IDP-023, with Sanofi’s CD38-targeting monoclonal antibody, Sarclisa (isatuximab).

Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated cell therapies for the treatment of cancer and autoimmune diseases, today announced the presentation of clinical and preclinical data at the Society for Immunotherapy of Cancer meeting in Houston, TX.

Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated cell therapies for the treatment of cancer and autoimmune diseases, today announced that the U.S. FDA has cleared the IND for the company’s Phase 1 clinical trial of its g-natural killer (g-NK) cell therapy, IDP-023, in progressive multiple sclerosis (MS).

Indapta Therapeutics, Inc., a privately held biotechnology company developing differentiated cell therapies for the treatment of cancer and autoimmune diseases, announced that CEO Mark Frohlich, MD, will be giving a plenary talk today titled, “g-NK cells for the treatment of cancer and autoimmune disease” at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference.

Indapta Therapeutics, Inc., a privately held biotechnology company developing next-generation differentiated cell therapies for the treatment of cancer and autoimmune diseases, today announced that Cancer Prevention and Research Institute of Texas (CPRIT) has granted the company a competitive product development research award. The $4.5 million grant will support Indapta’s ongoing clinical development of its lead product, IDP-023, for patients with advanced non-Hodgkin’s lymphoma and multiple myeloma.

Indapta Therapeutics, Inc., a privately held biotechnology company developing next-generation differentiated cell therapies for the treatment of cancer and other immune-mediated diseases, today announced that the U.S. FDA has granted Fast Track designation for its lead clinical program, IDP-023, for the treatment of patients with non-Hodgkin’s lymphoma and multiple myeloma.

Indapta Therapeutics, Inc., a privately held biotechnology company developing IDP-023, a natural killer (NK) cell therapy for the treatment of cancer, today announced that the company has initiated treatment of the first patients in its Phase 1 trial in multiple myeloma and Non-Hodgkin’s lymphoma. The patients were treated at the University of Texas MD Anderson Cancer Center and NEXT Oncology, Virginia.

Indapta Therapeutics, Inc., a privately held biotechnology company developing an NK (natural killer) cell therapy platform for the treatment of blood and solid tumor cancers, today announced it has appointed Moya Daniels as Senior Vice President of Regulatory, Quality and Clinical Operations.

Indapta Therapeutics, Inc., a privately held biotechnology company developing an NK (natural killer) cell therapy platform for the treatment of blood and solid tumor cancers, today announced it has appointed Mark W. Frohlich, M.D., chief executive officer and raised over $50 million in Series A financing and commitments co-led by RA Capital Management, LP, Vertex Ventures HC and Leaps by Bayer, the impact investment arm of Bayer AG. The Myeloma Investment Fund, the venture philanthropy subsidiary of the Multiple Myeloma Research Foundation, and Lonza also participated in the round. In connection with the financing, Laura Stoppel, Ph.D., principal at RA Capital Management, LP, Lori Hu, managing director at Vertex Ventures HC, and Fabio Pucci, Ph.D., senior director of venture investments health at Leaps by Bayer, joined Indapta’s board of directors.

Indapta Therapeutics, Inc., a biotechnology company developing and commercializing an NK (natural killer) cell therapy platform for the treatment of blood cancers and solid tumors, today announced the publication of new preclinical data in Blood Advances demonstrating Indapta’s proprietary allogeneic FcεRIγ-deficient G-NK cells in combination with an FDA-approved monoclonal antibody (mAb) resulted in greater than 99.9% tumor reduction in a preclinical cancer regression model of multiple myeloma compared to conventional NK cells. G-NK cells are a naturally occurring subset of NK cells that when expanded and “turbocharged” using Indapta’s proprietary manufacturing process, boost the efficacy of mAbs and can overcome the cost, inconsistency, and possible toxicities associated with autologous T-cell therapies commonly used in the treatment of multiple myeloma.